The goal of the presented research was to evaluate immunogenicity of the inactivated emulsified avian influenza (AI) type A (H5N1) vaccine that was developed on the basis of epizootically important autogenic AI virus strain A/domestic goose/Pavlodar/1/05 (H5N1) isolated in the epizooty focus in Pavlodarskaya oblast, Republic of Kazakhstan, in 2005. The results of the performed study show high level of vaccine immunogenicity. The vaccine is able to form the immunity for 12 months in 2-months chickens immunized in dose of 0.5 ml. The antihemagglutinating antibodies were detected in 14 days and reached their peak of 1:277 on the 6 th week post vaccination. The vaccination effectiveness is 100% from the 28 th day till the 150 th day post vaccination, then slowly decreases down to the level of 80% till day 360 post immunization (period of observation) that is sufficient for ensuring the safety of the vaccinated birds. Moreover the vaccine has high level of protectiveness demonstrating 100% protection of vaccinated birds on the 28 th day post vaccination and preventing virus shedding from cloaks and tracheas of chickens challenged with a field strain. The results of the study allow concluding that the developed inactivated emulsified AI vaccine of subtype H5 on the basis of the A/domestic goose/Pavlodar/1/05 (H5N1) possesses high protective ability and long-term immunogenicity.
INTRODUCTION
Avian influenza viruses are highly contagious and variable viruses that are widely spread among wild water and shore birds (Horimoto et al., 2001) . The agent includes three most significant subtypes H5, H7 and H9 demonstrating high pathogenicity for domestic birds and at the same time the epidemic potential posing the threat of the global pandemic (Webby et al., 2003 , Webster et al., 2006 . According to WHO experts among the named varieties of the avian influenza (AI) virus the strains A (H5N1) are of the greatest concern first of all because of high mutagenicity (Klempner et al., 2004 , Webster et al., 2006 . By June 2, 2009 the disease has been registered in 62 countries of the globe (WHO, 2009/02/06) . As it concerns the scale of spread and the caused economical loss the AI virus A (H5N1) considerably surpasses all reported similar outbreaks of the disease ever registered in the world. During the period from 1997 through 2009 over 15⋅10 7 domestic birds died and were euthanized because of the disease outbreaks in the countries of the SouthEastern Asia, Russia, Turkey, Ukraine, Romania, Georgia, Azerbaijan, Nigeria, Egypt and some other countries (Webster et al., 2006) . Moreover 433 humans were infected and 262 of them died (WHO, 2009 ). In Kazakhstan highly pathogenic avian influenza A (H5N1) was first recorded on July 22, 2005 among birds of "Nan" farm in Golubovka village of Irtyshskiy rayon (district), Pavlodarskaya oblast (province). Later on the disease spread to Akkolskiy and Korgaljinskiy rayons of Akmolinskaya oblast, Kyzylzharskiy, Zhambylskiy and Mamlyutinskiy rayons of of Severo-Kazakhstanskaya (NorthKazakhstan) oblast, Shetskiy rayon of Karagandinskaya oblast. In all above mentioned infected areas 12860 domestic birds were withdrawn and euthanized. Owing to the implemented complex measures further spread of the disease was stopped, avian influenza foci were localized and infection among people in the republic was prevented. However all counter-epizootic actions failed to prevent reoccurrence of the infection. On March 21, 2006 a dead wild swan was found in Manghistauskaya oblast. Assay of the pathology material from this bird at the RIBSP showed the presence of the avian influenza virus (AIV) of type A/H5N1. In the course of the epizooty in this oblast 70 wild birds in total died of AI H5N1. The infection among domestic birds was not registered (Khairullin, 2007 , Amanzholova et al., 2008 . The critical situation with the HPAI A (H5N1) demonstrating high epidemiological potential in the world impelled many countries including Kazakhstan (RIBSP in particular) to urgently develop a vaccine against this especially dangerous disease. The RIBSP's specialists developed a vaccine on the basis of the epizootically important AI virus strain A/domestic goose/Pavlodar/1/05 (H5N1) isolated from the pathology material taken in the infection focus in Pavlodarskaya oblast in 2005 (Qiao et al., 2003) . The virus was grown in the system of specific pathogenfree (SPF) embryonated eggs according to the specified cultivation parameters which allow raising highly active virus-containing material for production of inactivated vaccines . The virus was inactivated with dimer ethyleneimine (DEI) that ensured more stable and reliable virus inactivation while keeping safe the original antigen activity versus formalin and beta-propiolactone which are widely used in production of influenza vaccines . Commercial oil adjuvant Montanide ISA-70 (Seppic, France) is present in the vaccine as an immunostimulating agent in the ratio recommended by its producer. In this study the effectiveness of the developed vaccine was evaluated under experimental conditions by testing its immunogenicity in chickens.
MATERIALS AND METHODS

Description of the production virus:
Epizootic autogenic strain A/domestic goose/Pavlodar/1/05 H5N1 of avian influenza virus (AIV) isolated in the disease focus ("NAN" farm, Golubovka village, Abaiskiy rural district, Irtyshskiy rayon, Pavlodarskaya oblast) in July of year 2005 was used to develop a vaccine against avian influenza of H5 subtype. The virus was isolated from the pathology materials (brain, lungs, trachea, intestine) taken from a dead domestic goose on the 10-days SPF-embryos and identified by molecularbiological and serological methods . In the genetic aspect AIV strain A/domestic goose/Pavlodar/1/05 H5N1 belongs to the Qinghai/Siberia cluster (сlad 2.2), is identical to a vast line of highly pathogenic AIV (HPAIV) A/goose/Guangdong/1/96 (H5N1) isolates detected on the territory of the South-Eastern Asia (including Indonesia) and China starting from 1996 till present time (Mamadaliyev et al., 2008) . The virus is pathogenic in chickens, ducks, geese and turkeys (intravenous pathogenicity index is 2.3). A/domestic goose/Pavlodar/1/05 H5N1 strain was deposited into the Microbial Collection of the RIBSP/RK NBC/SC RK ME&S under the registration number M-3-07/D on January 10, 2007 and patented at the RK National Patent Agency. Vaccine preparation Virus-containing suspension was produced in 12-days SPF-embryos via their infection with 500 EID 50 into allantoic cavity and incubation at 36°C for 36-38 hours. The produced virus suspension was inactivated with DEI (C 4 H 10 N 2 , Biochemresource, Vladimir City, Russian Federation) in the final concentration 0.2% at 37°C for 30 hours. The infective and hemagglutinating activity of the viral suspension before inactivation was 9.1 lg 50% egg infective doses (EID 50 )/ml and 1:512, respectively. Inactivation completeness was controlled in SPFembryos in compliance with the O.I.E. adopted procedure (OIE, 2004) . The vaccine was prepared by mixing oil adjuvant Montanide ISA-70 (Seppic, France) and pre-clarified (3000 rpm, 30 min) inactivated antigen of the virus in ratio 7:3 and their thorough stirring by using the laboratory homogenizer T25 basic ULTRA-TURRAX, IKA (Germany) (3000 rpm, 10-15 min) until stable white emulsion. In addition the vaccine was supplemented with gentamicin (200 mg/dm 3 ) and thimerosal (0.102 mg/dm 3 ). The entire process of preparing laboratory specimens of the inactivated vaccine with use of the production strain was carried out under conditions of the Biological Safety Laboratory 3. Terms of immunity formation and duration in vaccinated birds: A group of twenty 2-months chickens of Jaffa cross that were free of acute infectious diseases and seronegative to influenza virus A were vaccinated intramuscularly with the inactivated vaccine in dose 0.5 ml. To see the dynamics of antihemagglutinating (AH) antibodies formation in vaccinated birds they were bled in 7, 14, 28, 42 days post vaccination and every month further on and the blood samples were assayed in the hemagglutination inhibition (HI) test according to WHO adopted procedure (WHO, 2002) . In HI test 4 hemagglutinating units (HAU) of DEI-inactivated production virus were used as an antigen. The resulted values of geometric mean titers of AH antibodies and number of seropositive birds (birds with AH antibodies titer 1:16 and higher in HI test) were used in curve plotting.
Evaluation of the vaccine protective efficacy:
Vaccine protective efficacy was assessed by the challenge of vaccinated (n=4) th days post infection) to reveal possible virus shedding. The birds were housed in an isolator, ventilated under negative pressure with HEPA filtered air, and maintained under continuous lighting. Appropriate food and water was provided ad libitum. All the animal experiments were conducted in biosafety level 3 containment facilities and all personnel was required to use respiratory protection when working with live viruses or the experimentally infected animals. Virus isolation: Swab samples collected for virus isolation were placed in vials with 2 ml of transport medium (2.5% Veal Infusion Broth, 0.5% Bovine Serum Albumin, gentamicin -100 µg/ml, fungizone -2 µg/ml) and stored at -70°C until use. For virus isolation the samples were clarified by centrifugation at 3,000 × g for 10 min and by filtration through 0.8 µ non-protein binding filter disc using a syringe followed by filtering through a 0.2 µ filter. Later on 10-fold dilutions of the purified transport medium in the sterile PBS (10 -1 -10 -7
) were prepared. Starting with the highest dilution (10 -7 ) each material dilution (including intact material) was used to infect 4 SPF embryos into allantoic cavity in dose 0.2 cm 3 . The infected embryos were incubated at 36°С for 72 h with daily ovoscopy. The virus presence in embryos after cooling (at 4°C for 16 h) was determined in the qualitative hemagglutination test (HA test) according to the WHO Manual on Animal Influenza Diagnosis and Surveillance (WHO, 2002) . The virus titers were estimated according to L. Reed and H. Muench (Reed et al., 1938) 
DISCUSSION
In the system of AI control measures vaccination is one of the most important. The world practice showed high effectiveness of counter-epidemic measures in complex with vaccine prophylaxis as it was demonstrated in the USA, Mexico, Pakistan and Italy. Currently mass vaccination of domestic birds against highly pathogenic avian influenza A (H5N1) is carried out in China, Vietnam, Indonesia, Sudan and Egypt (Peyre et al., 2007) .
At present day a number of commercially available vaccines produced by about 30 companies in China, France, Holland, Mexico, USA, Italy, Germany, Japan, Indonesia and Russia are used for specific prophylaxis of the avian influenza A (H5N1). All these vaccines are inactivated emulsified and live recombinant vaccines based on the chicken pox and Newcastle disease viruses (FAO, 2006) .
Immunogenicity of these vaccines varies depending on the production strain (autogenic or heterogeneous, constructed by the method of reverse genetics or without it), dose and administration multiplicity. According to Liu M et al. (2003) the inactivated vaccine (Intervet) based on the heterogeneous strain A/CK/Mexico/232/94 (H5N2) formed 12-month-long immunity in twice vaccinated chickens. The geometric mean antibody titer was 1:100 on the 28 th day after the first vaccination and 1:333 after the second immunization. Challenge of the vaccinated birds with A/CK/HK/86.3/02 (H5N1) strain in dose 100 CLD 50 (50% chicken lethal doses) resulted in death of 10% of infected birds; 30% shed the virus into the environment thus causing the death of 50% of intact birds that were in contact with the infected ones. Judging on the serological parameters the vaccine had expressed immunogenicity but its protective efficiency was not reliable enough in the result of using a genetically far-related heterogeneous strain the single advantage of which was the ability to differentiate infected and vaccinated birds (DIVA strategy) (Capua et al., 2002) .
The best results in improving AI A (H5N1) vaccine immunogenicity were first obtained by the researchers of the Harbin Veterinary Research Institute. Under experimental conditions their vaccine on the basis of autogenic H5N1/PR8 strain (constructed by the method of reverse genetics) induced expressed 10-month-long immunity in SPF chickens after single administration. The maximal level of antibodies 1:1024 was recorded on the 6 th week. Moreover the vaccine demonstrated high immunogenicity in domestic ducks and geese that is very important for counter-epizootic actions. Morbidity and mortality of the vaccinated chickens, ducks and geese was not observed at their challenge with the highly pathogenic strain A/goose/Guangdong/1/96 (H5N1) in dose 7.5 log EID 50 , though insignificant virus shedding into environment was reported (Tian et al., 2005 , Qiau et al., 2006 .
There are many reports on effectiveness of using live recombinant vaccines based on chicken pox and Newcastle disease viruses with expressed gene of epizootically actual AIV strains in prophylaxis of the highly pathogenic avian influenza A (H5N1) (Qiao et al., 2003 , Veits et al., 2006 , Ge et al., 2007 . The most important advantage of the live recombinant vaccines is their ability to rapidly form adequate immunity (humoral and cellular) as soon as on the 7 th day after single vaccination. One of their most significant disadvantages is their low immunogenicity in adult chickens and total lack of immunogenicity in water poultry (geese and ducks) after vaccination (Veits et al., 2006) . The cause of this high immunogenicity of the developed vaccines is the use of autogenic AIV strain A/domestic goose/Pavlodar/1/05 (H5N1) that is able to reproduce in the system of chicken embryos to titers of infectious and hemagglutinating activity exceeding 9.0 lg EID 50 /cm 3 and 1:512 respectively . One more attribute of the vaccine is inactivating agent DEI that is used to inactivate the virus. Its advantage consists in its inactivating effect on the nucleic acid only but not on the viral proteins as it happens in case of using formaldehyde and beta-propiolactone .
It has been reported that use of inactivated vaccine with NA marker enables to differentiate infected and vaccinated birds (DIVA) (Capua et al., 2002) . The latest monitoring data reveal circulation and existence of many influenza viruses with different combinations of HA and NA in the poultry population in China. Due to this fact use of subtype NA as a marker for differentiation of infected from vaccinated birds is impossible (Cauthen et al., 2000 , He et al., 2003 .
According to Qiao et al. (2003) the recombinant virus of chicken pox containing HA and NA genes of AI virus H5N1 ensures complete protection of the vaccinated birds challenged with AI virus H7N1 against the lethal infection. It means that NA protein is also very important in providing vaccine efficiency. Because of this in the research described here autogenic strain with higher protective efficiency as compared to heterogeneous strains was selected to develop an effective vaccine for highly pathogenic avian influenza H5N1.
On the basis of the above stated the conclusion can be made that the inactivated emulsified vaccine based on A/domestic goose/1/05 (H5N1) strain that has been developed by the authors possesses high protective efficiency and long-term immunogenicity. Because of this it can be used (after field testing) in practical veterinary medicine for prophylactic immunization of domestic birds against highly pathogenic avian influenza A (H5N1).
